BRPI0418805A - construção de recombinante de adenovìrus oncolìtico expressando especificamente um fator imunomodulatório gm-csf em células tumorais e seus usos - Google Patents

construção de recombinante de adenovìrus oncolìtico expressando especificamente um fator imunomodulatório gm-csf em células tumorais e seus usos

Info

Publication number
BRPI0418805A
BRPI0418805A BRPI0418805-5A BRPI0418805A BRPI0418805A BR PI0418805 A BRPI0418805 A BR PI0418805A BR PI0418805 A BRPI0418805 A BR PI0418805A BR PI0418805 A BRPI0418805 A BR PI0418805A
Authority
BR
Brazil
Prior art keywords
csf
tumor cells
oncolytic adenovirus
immunomodulatory factor
specifically expressing
Prior art date
Application number
BRPI0418805-5A
Other languages
English (en)
Inventor
Zunhong Ke
Original Assignee
Chengdu Kanghong Biotechnologi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Kanghong Biotechnologi filed Critical Chengdu Kanghong Biotechnologi
Publication of BRPI0418805A publication Critical patent/BRPI0418805A/pt
Publication of BRPI0418805B1 publication Critical patent/BRPI0418805B1/pt
Publication of BRPI0418805B8 publication Critical patent/BRPI0418805B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CONSTRUçãO DE RECOMBINANTE DE ADENOVìRUS ONCOLìTICO EXPRESSANDO ESPECIFICAMENTE UM FATOR IMUNOMODULATóRIO GM-CSF EM CéLULAS TUMORAIS E SEUS USOS . A presente invenção relaciona-se à terapia do gene para tumores, especificamente, a terapia relaciona-se à construção do adenovírus oncolítico recombinado, que expressa especificamente um fator imunomodulatório GM-CSF em células tumorais e seus usos.
BRPI0418805A 2004-06-07 2004-11-19 construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos BRPI0418805B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200410046237.X 2004-06-07
CNB200410046237XA CN100361710C (zh) 2004-06-07 2004-06-07 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
PCT/CN2004/001321 WO2005121343A1 (en) 2004-06-07 2004-11-19 Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0418805A true BRPI0418805A (pt) 2007-10-16
BRPI0418805B1 BRPI0418805B1 (pt) 2021-01-26
BRPI0418805B8 BRPI0418805B8 (pt) 2021-05-25

Family

ID=35503069

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418805A BRPI0418805B8 (pt) 2004-06-07 2004-11-19 construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos

Country Status (12)

Country Link
US (1) US7951585B2 (pt)
EP (1) EP1767642B1 (pt)
JP (1) JP4874247B2 (pt)
CN (1) CN100361710C (pt)
BR (1) BRPI0418805B8 (pt)
CA (1) CA2568995C (pt)
DK (1) DK1767642T3 (pt)
ES (1) ES2466415T3 (pt)
PL (1) PL1767642T3 (pt)
PT (1) PT1767642E (pt)
RU (1) RU2361611C2 (pt)
WO (1) WO2005121343A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090142294A1 (en) * 2005-01-25 2009-06-04 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
EP2586459B1 (en) 2005-03-25 2017-05-24 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations
EP3753548A1 (en) 2006-06-16 2020-12-23 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
JP2008048621A (ja) * 2006-08-22 2008-03-06 Chiba Prefecture キメラ型アデノウイルスとその作製方法並びにそれを用いた医薬
CN101391104B (zh) * 2007-09-21 2010-10-06 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的新用途
RU2013118724A (ru) 2010-09-24 2014-10-27 Онкос Терапьютикс Ой Онколитические аденовирусные векторы и связанные с ними способы и применения
JP6093712B2 (ja) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン２のスーパーアゴニストおよびアンタゴニスト
KR20200077622A (ko) 2011-01-13 2020-06-30 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
US9624476B2 (en) 2011-08-23 2017-04-18 National Institute Of Biomedical Innovation Conditionally replicating adenovirus
KR101946666B1 (ko) * 2011-08-23 2019-02-11 고쿠리츠 켄큐 카이하츠 호진 이야쿠 키반 켄코 에이요 켄큐쇼 제한 증식형 아데노바이러스
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
IN2014DN06898A (pt) * 2012-03-14 2015-05-15 Salk Inst For Biological Studi
US9017672B2 (en) 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
KR102089121B1 (ko) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양살상형 아데노바이러스 조성물
EP2978854A4 (en) * 2013-03-24 2017-01-11 Oisin Biotechnologies Systems and methods for the targeted production of a therapeutic protein within a target cell
EP2987858B1 (en) * 2013-04-17 2019-08-14 Kyushu University, National University Corporation Gene-modified coxsackievirus
SI3021859T1 (en) 2013-10-25 2018-04-30 Psioxus Therapeutics Limited Oncolytic adenoviruses equipped with heterologous genes
RU2682762C2 (ru) * 2013-11-27 2019-03-21 Общество С Ограниченной Ответственностью "Панацела Лабс" Улучшенный вектор, экспрессирующий toll-подобный рецептор и агонист, и применение в терапии рака
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
EP3198009B1 (en) 2014-09-24 2021-09-08 Salk Institute for Biological Studies Oncolytic tumor viruses and methods of use
US11000559B2 (en) 2015-04-30 2021-05-11 Psioxus Therapeutics Limited Oncolytic adenovirus encoding a B7 protein
CN108697745A (zh) 2015-12-17 2018-10-23 皮斯奥克斯治疗公司 编码抗tcr复合体抗体或片段的b组腺病毒
JP7015551B2 (ja) 2016-02-23 2022-02-15 ソーク インスティテュート フォー バイオロジカル スタディーズ ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
JP7794421B2 (ja) 2016-12-12 2026-01-06 ソーク インスティテュート フォー バイオロジカル スタディーズ 腫瘍を標的にする合成アデノウイルスおよびその使用
WO2018129563A1 (en) 2017-01-09 2018-07-12 Oisin Biotechnologies Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
JP7433051B2 (ja) * 2017-06-19 2024-02-19 メディシナ セラピューティクス インコーポレイテッド Ｉｌ－２スーパーアゴニスト、アゴニスト、およびそれらの融合体の使用および方法
IL274711B2 (en) 2017-11-30 2024-10-01 Regeneron Pharma Use of a vegf antagonist to treat angiogenic eye disorders
CN111630159A (zh) * 2017-12-13 2020-09-04 基因药物株式会社 重组腺病毒及包含此病毒的干细胞
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
US11603543B2 (en) 2018-04-18 2023-03-14 Oisin Biotechnologies, Inc. Fusogenic lipid nanoparticles for target cell-specific production of a therapeutic protein
EP4079750A3 (en) 2018-11-21 2023-01-04 Mayo Foundation for Medical Education and Research Adenoviruses and methods for using adenoviruses
WO2020166727A1 (ja) * 2019-02-12 2020-08-20 国立大学法人大阪大学 ヒト３５型アデノウイルスを基板とした腫瘍溶解性ウイルス
IL292788B2 (en) 2019-04-29 2023-12-01 Mayo Found Medical Education & Res Multivalent pd-l1 binding compounds for treating cancer
EP4123021A4 (en) * 2020-03-23 2024-05-15 Curigin Co.,Ltd. STRUCTURE OF AN ONCOLYTIC VIRUS WITH BISPECIFIC NUCLEIC ACID MOLECULE
WO2021226444A2 (en) 2020-05-08 2021-11-11 Regeneron Pharmaceuticals, Inc. Vegf traps and mini-traps and methods for treating ocular disorders and cancer
RU2753742C1 (ru) * 2020-10-16 2021-08-24 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Рекомбинантный штамм Ad6-hTERT-GMCSF, содержащий встройку промотора теломеразы человека hTERT, а также гена гранулоцитарно-макрофагального колониестимулирующего фактора человека, обладающий избирательной цитолитической активностью против теломераза-положительных опухолевых клеток и экспрессирующий активный человеческий гранулоцитарно-макрофагальный колониестимулирующий фактор
CN115029325A (zh) * 2021-03-08 2022-09-09 南京惟亚德生物医药有限公司 一种重组溶瘤腺病毒及其应用
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592317B1 (en) * 1994-08-11 2009-09-22 The University Of Chicago Constitutive gene expression in conjuction with ionizing radiation
WO1996009399A2 (en) 1994-09-23 1996-03-28 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
WO1999046371A2 (en) 1998-03-11 1999-09-16 Board Of Regents, The University Of Texas System Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
JP2002512785A (ja) * 1998-04-24 2002-05-08 オニックス ファーマシューティカルズ，インコーポレイティド 疾患治療用のアデノウイルスベクター
US6627190B2 (en) 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
GB9916851D0 (en) * 1999-07-20 1999-09-22 Univ Wales Bangor Manipulation of particles in liquid media
DE60035124T2 (de) 1999-11-15 2008-02-07 Onyx Pharmaceuticals, Inc., Emeryville Ein oncolytisches adenovirus
ES2256302T3 (es) * 2000-08-10 2006-07-16 Crucell Holland B.V. Vectores adenovirales para la transduccion de condrocitos.
US6713055B2 (en) 2000-11-27 2004-03-30 Geron Corporation Glycosyltransferase vectors for treating cancer
IL152420A0 (en) * 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
CN1177053C (zh) * 2001-04-13 2004-11-24 上海华康生物技术有限公司 靶向性、高表达人粒细胞巨噬细胞集落刺激因子的重组腺病毒及其制法和用途
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
JP2005502645A (ja) * 2001-08-08 2005-01-27 ザ ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 細胞特異的プロモーターからの発現を増幅するための方法
JP3867968B2 (ja) * 2002-07-08 2007-01-17 関西ティー・エル・オー株式会社 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
CN1259106C (zh) * 2002-12-23 2006-06-14 中国科学院上海生命科学研究院 一种抗癌靶向基因病毒药物的制备方法
ES2292271B1 (es) * 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.

Also Published As

Publication number Publication date
CA2568995E (en) 2005-12-22
EP1767642A1 (en) 2007-03-28
CN1706955A (zh) 2005-12-14
EP1767642B1 (en) 2014-04-23
CA2568995C (en) 2012-02-21
BRPI0418805B8 (pt) 2021-05-25
JP2008501349A (ja) 2008-01-24
BRPI0418805B1 (pt) 2021-01-26
DK1767642T3 (da) 2014-05-26
CA2568995A1 (en) 2005-12-22
PT1767642E (pt) 2014-06-03
WO2005121343A1 (en) 2005-12-22
ES2466415T3 (es) 2014-06-10
RU2006146665A (ru) 2008-07-20
RU2361611C2 (ru) 2009-07-20
JP4874247B2 (ja) 2012-02-15
US7951585B2 (en) 2011-05-31
CN100361710C (zh) 2008-01-16
PL1767642T3 (pl) 2014-08-29
EP1767642A4 (en) 2008-06-25
US20100047208A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
BRPI0418805A (pt) construção de recombinante de adenovìrus oncolìtico expressando especificamente um fator imunomodulatório gm-csf em células tumorais e seus usos
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
MX2013012167A (es) Estratificaciones a base de bcma y terapia para pacientes con mieloma multiple.
CR11519A (es) Vectores de virus oncoliticos de viruela
CY1122654T1 (el) Ενωσεις για βελτιωμενη iiκη μεταγωγη
BRPI0510475A (pt) adenovìrus quimérico para o uso no tratamento de cáncer
EP4523696A3 (en) Enhanced adoptive cell therapy
CL2009000082A1 (es) Acido nucleico que codifica anticuerpos anti cd79a o anti cd79b para el tratamiento de tumores hematopoyeticos; vector y células huésped que los comprenden; polipeptido codificado por dicho acido nucleico, inmunoconjugado con el cuerpo.
MX2012004868A (es) Proteinas de enlace al antigeno il-23 humanas.
DOP2015000050A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
CL2013001138A1 (es) Composicion que comprende anticuerpo biespecífico cd19xcd3 para tratar masa tumoral de tejido de ganglios linfáticos y/o linfoma extranodal causado por el linfoma b difuso de células grandes (lbdcg); kit farmacéutico; uso de la composición.
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
ME01327B (me) Humana antitela visokog afiniteta prema pcsk9
ATE485066T1 (de) Medizinische ballons mit modifizierten oberflächen
CU20120095A7 (es) Antagonistas de pcsk9
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
CR11520A (es) Vectores de virus oncoliticos de viruela
WO2008106646A3 (en) Methods and formulations for topical gene therapy
EP3799871A3 (en) Pyrazol-3-ones that activate pro-apototic bax
ITBO20080047A1 (it) Azionamento elettrico e metodo di pilotaggio dello stesso.
PL1863905T3 (pl) Sposób aktywacji naturalnych komórek zabójców preparatami komórek guza in vitro
MX2010003110A (es) Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.
BR112022005963A2 (pt) Células com expressão de transgenes sustentada
ATE549638T1 (de) 13c-mr-bildgebung oder spektroskopie von zelltod

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF